Physician
Dalia, Himani
Dalia, Himani was paid $3.87M by Medicaid between Jan 2018 and Nov 2024, across 137 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 15% of everything it billed.
33Billing provider infoDALIA, HIMANI
WAUKEGAN, IL 60085
WAUKEGAN, IL 60085
33aNPI1780684670assigned 07/21/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$3.87M
24GClaims701,187
24DCodes billed137
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#17 of 398
Median peer was paid$66K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 111,157 | $517K | |
| 2019 | 140,646 | $650K | |
| 2020 | 123,291 | $616K | |
| 2021 | 106,519 | $749K | |
| 2022 | 95,208 | $660K | |
| 2023 | 82,509 | $453K | |
| 2024incomplete | 41,857 | $227K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15% | 24,048 | 19,409 | $571K |
| 80053 | Comprehensive metabolic panel | 11% | 81,703 | 55,051 | $418K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7.2% | 8,678 | 7,076 | $280K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.9% | 93,396 | 56,347 | $266K |
| 87428 | 4.1% | 4,298 | 4,059 | $159K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 2,036 | 1,759 | $121K |
| 83735 | 2.8% | 32,353 | 16,281 | $108K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.7% | 4,704 | 4,379 | $105K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 4,689 | 4,366 | $105K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.6% | 12,749 | 11,229 | $103K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 24,191 | 11,274 | $98K |
| 84484 | 2.2% | 21,921 | 15,897 | $86K |
125 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.0% | 9,848 | $77K |
| 87040 | 2.0% | 8,534 | $77K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.9% | 5,332 | $74K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.9% | 14,217 | $72K |
| 83690 | 1.6% | 18,082 | $60K | |
| 85027 | 1.5% | 20,350 | $58K | |
| 81025 | 1.5% | 28,295 | $56K | |
| 83880 | 1.3% | 5,277 | $52K | |
| 82805 | 1.3% | 5,048 | $52K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 1,509 | $47K |
| 81001 | 1.1% | 32,795 | $42K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.1% | 1,232 | $41K |
| 82962 | <1% | 18,887 | $34K | |
| 84100 | <1% | 15,414 | $33K | |
| 83605 | <1% | 7,174 | $33K | |
| 87807 | <1% | 5,854 | $30K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,473 | $29K |
| 80061 | Lipid panel | <1% | 8,500 | $28K |
| 86901 | <1% | 11,935 | $28K | |
| 86850 | <1% | 8,498 | $24K | |
| 86900 | <1% | 11,935 | $21K | |
| 85610 | <1% | 10,485 | $20K | |
| 87806 | <1% | 2,031 | $20K | |
| 85379 | <1% | 4,979 | $18K | |
| 84702 | <1% | 3,951 | $17K | |
| 85730 | <1% | 5,366 | $17K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 469 | $16K |
| 81003 | <1% | 14,519 | $15K | |
| 82261 | <1% | 1,648 | $13K | |
| 87186 | <1% | 2,176 | $13K | |
| 82550 | <1% | 4,624 | $13K | |
| 84439 | <1% | 2,957 | $13K | |
| 80202 | <1% | 1,807 | $12K | |
| 83498 | <1% | 1,995 | $12K | |
| 82607 | <1% | 1,956 | $12K | |
| 84703 | <1% | 3,149 | $11K | |
| 87070 | <1% | 3,484 | $10K | |
| 83520 | <1% | 1,634 | $10K | |
| 88307 | <1% | 284 | $10K | |
| 80074 | <1% | 518 | $10K | |
| 82570 | <1% | 4,505 | $10K | |
| 82803 | <1% | 1,379 | $9K | |
| 87340 | <1% | 1,337 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 622 | $8K |
| 86140 | <1% | 3,480 | $8K | |
| 86803 | <1% | 903 | $8K | |
| 82728 | <1% | 1,904 | $7K | |
| 82016 | <1% | 1,990 | $7K | |
| 87210 | <1% | 3,069 | $7K | |
| 88342 | <1% | 390 | $6K | |
| 83020 | <1% | 1,508 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 276 | $6K |
| 82776 | <1% | 1,996 | $6K | |
| 87205 | <1% | 3,241 | $6K | |
| 87077 | <1% | 1,892 | $6K | |
| 85007 | <1% | 3,447 | $6K | |
| 82128 | <1% | 1,648 | $6K | |
| 82746 | <1% | 965 | $6K | |
| 84550 | <1% | 2,693 | $5K | |
| 82760 | <1% | 1,990 | $5K | |
| 83550 | <1% | 1,285 | $5K | |
| 87081 | <1% | 1,826 | $5K | |
| 83615 | <1% | 1,843 | $5K | |
| 83540 | <1% | 1,557 | $5K | |
| 84030 | <1% | 1,647 | $4K | |
| 86592 | <1% | 1,991 | $4K | |
| 82077 | <1% | 359 | $4K | |
| 86880 | <1% | 1,203 | $4K | |
| 82565 | <1% | 1,439 | $3K | |
| 82248 | <1% | 1,415 | $3K | |
| 82140 | <1% | 752 | $3K | |
| 82247 | <1% | 1,101 | $3K | |
| 82043 | <1% | 1,130 | $2K | |
| 84156 | <1% | 2,274 | $2K | |
| 84300 | <1% | 1,033 | $2K | |
| 85651 | <1% | 892 | $2K | |
| 87015 | <1% | 646 | $2K | |
| 82150 | <1% | 630 | $2K | |
| 85018 | <1% | 1,837 | $2K | |
| 85014 | <1% | 1,414 | $1K | |
| 87493 | <1% | 61 | $1K | |
| 87045 | <1% | 199 | $1K | |
| 86038 | <1% | 154 | $1K | |
| 82330 | <1% | 177 | $1K | |
| 84481 | <1% | 190 | $932.24 | |
| 80164 | <1% | 208 | $907.98 | |
| 87632 | <1% | 29 | $812.00 | |
| 86696 | <1% | 61 | $696.90 | |
| 84152 | <1% | 96 | $684.00 | |
| 85652 | <1% | 516 | $668.64 | |
| 87449 | <1% | 78 | $666.40 | |
| 80050 | General health panel | <1% | 49 | $594.50 |
| 86039 | <1% | 104 | $554.46 | |
| 82947 | <1% | 387 | $478.99 | |
| 82950 | <1% | 200 | $477.60 | |
| 82436 | <1% | 205 | $477.11 | |
| 86695 | <1% | 53 | $451.35 | |
| 84133 | <1% | 212 | $446.76 | |
| 87116 | <1% | 75 | $428.85 | |
| 88312 | <1% | 28 | $423.53 | |
| 87427 | <1% | 80 | $393.04 | |
| 87209 | <1% | 48 | $358.64 | |
| 88304 | <1% | 15 | $336.12 | |
| 87147 | <1% | 184 | $292.80 | |
| 87075 | <1% | 51 | $262.64 | |
| 86870 | <1% | 34 | $243.78 | |
| 82009 | <1% | 232 | $233.96 | |
| 87046 | <1% | 187 | $220.05 | |
| 85384 | <1% | 76 | $215.66 | |
| 87206 | <1% | 93 | $204.11 | |
| 87177 | <1% | 48 | $171.40 | |
| 84132 | <1% | 161 | $159.75 | |
| 80069 | <1% | 28 | $119.28 | |
| 82105 | <1% | 13 | $106.29 | |
| 86308 | <1% | 44 | $105.48 | |
| 85378 | <1% | 20 | $69.80 | |
| 89051 | <1% | 21 | $68.20 | |
| 83930 | <1% | 21 | $51.26 | |
| 82945 | <1% | 33 | $50.82 | |
| 86431 | <1% | 13 | $47.06 | |
| 88141 | <1% | 13 | $44.87 | |
| 84157 | <1% | 35 | $40.25 | |
| 84295 | <1% | 22 | $19.84 | |
| 85045 | <1% | 18 | $18.34 | |
| 86923 | 0% | 119 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.